MedPacto Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
47
- Stock Symbol
-
235980
- Investments
-
1
- Share Price
-
$3.19
- (As of Friday Closing)
MedPacto General Information
Description
MedPacto Inc is a drug discovery and development company based in South Korea. It is engaged in developing anticancer drugs and medicines which focuses on therapeutics targeting cancer and autoimmune diseases. Its products are in pipeline.
Contact Information
Website
www.medpacto.comCorporate Office
- 92 Myeongdal-ro, Seocho-gu
- Borim Building
- Seoul, 06668
- South Korea
Corporate Office
- 92 Myeongdal-ro, Seocho-gu
- Borim Building
- Seoul, 06668
- South Korea
MedPacto Stock Performance
As of 13-Nov-2026, MedPacto’s stock price is $3.19. Its current market cap is $109M with 34.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.19 | $3.19 | $1.55 - $5.93 | $109M | 34.3M | 271K | -$0.28 |
MedPacto Financials Summary
As of 30-Jun-2026, MedPacto has a trailing 12-month revenue of $3.44M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 46,421 | 130,346 | 62,645 | 188,845 |
| Revenue | 3,442 | 2,739 | ||
| EBITDA | (9,520) | (8,978) | (14,800) | (25,536) |
| Net Income | (9,743) | (9,002) | (14,761) | (27,018) |
| Total Assets | 27,393 | 33,794 | 41,267 | 62,447 |
| Total Debt | 962 | 1,198 | 1,318 | 1,884 |
MedPacto Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MedPacto Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MedPacto Patents
MedPacto Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026182584-A1 | Triple combination therapy of immune checkpoint inhibitor, vegf/vegfr inhibitor, and tgf-β receptor signaling inhibitor | Pending | 28-Feb-2025 | ||
| WO-2026059289-A1 | Composition comprising tetraarsenic hexaoxide as active ingredient for treating or preventing metabolic dysfunction-associated fatty liver disease | Pending | 11-Sep-2024 | ||
| EP-4814009-A1 | Fusion protein specifically binding to extradomain b of fibronectin (edb-fn) and transforming growth factor beta (tgfb), and use thereof | Pending | 24-Nov-2023 | ||
| AU-2024384346-A1 | Fusion protein specifically binding to extradomain b of fibronectin (edb-fn) and transforming growth factor β (tgfβ), and use thereof | Pending | 24-Nov-2023 | ||
| WO-2025110822-A1 | Fusion protein specifically binding to extradomain b of fibronectin (edb-fn) and transforming growth factor β (tgfβ), and use thereof | Inactive | 24-Nov-2023 | C07K16/18 |
MedPacto Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MedPacto Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
MedPacto Investments (1)
MedPacto’s most recent deal was a Seed Round with Celloram for . The deal was made on 01-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Celloram | 01-Jan-2020 | Seed Round | Drug Discovery |
MedPacto ESG
Risk Overview
Risk Rating
Updated December, 31, 2023
35.33 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,744
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Pharmaceuticals
Subindustry
of 423
Rank
Percentile
MedPacto FAQs
-
When was MedPacto founded?
MedPacto was founded in 2013.
-
Where is MedPacto headquartered?
MedPacto is headquartered in Seoul, South Korea.
-
What is the size of MedPacto?
MedPacto has 47 total employees.
-
What industry is MedPacto in?
MedPacto’s primary industry is Drug Discovery.
-
Is MedPacto a private or public company?
MedPacto is a Public company.
-
What is MedPacto’s stock symbol?
The ticker symbol for MedPacto is 235980.
-
What is the current stock price of MedPacto?
As of 13-Nov-2026 the stock price of MedPacto is $3.19.
-
What is the current market cap of MedPacto?
The current market capitalization of MedPacto is $109M.
-
What is MedPacto’s current revenue?
The trailing twelve month revenue for MedPacto is $3.44M.
-
What is MedPacto’s annual earnings per share (EPS)?
MedPacto’s EPS for 12 months was -$0.28.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
